Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

http://www.wikidata.org/entity/Q34467233

about

Managing risks in drug discovery: reproducibility of published findings Recent advances in pathogenesis, assessment, and treatment of atherosclerosis From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications Unmet Needs in LDL-C Lowering: When Statins Won't Do!PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus Lipids, blood pressure and kidney update 2015 Low High-Density Lipoprotein and Risk of Myocardial Infarction Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia New developments in atherosclerosis: clinical potential of PCSK9 inhibition PCSK9 inhibition: the way forward in the treatment of dyslipidemia Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents Cardiovascular pharmacogenomics: current status and future directions New drugs for treating dyslipidemia: beyond statins Current therapies for lowering lipoprotein (a)Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders PCSK9 inhibitors in the prevention of cardiovascular disease The year in cardiology 2015: prevention New Era of Lipid-Lowering Drugs PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era PCSK9 inhibitors - mechanisms of action A Review of the Key Clinical Trials of 2015: Results and Implications Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases PCSK9 inhibitors - clinical applications Lowering cholesterol in chronic kidney disease: is it safe and effective?PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia Immune cell screening of a nanoparticle library improves atherosclerosis therapy Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Lipoprotein(a) in nephrological patients Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.Accuracy of low-density lipoprotein cholesterol estimation at very low levels.Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.

P2860

Q24289508-EB1304D0-2774-4CB2-9293-7ADF251758F6 Q26740304-1DC849B2-34ED-4579-8264-A7DF4769C783 Q26741078-D20EE95E-9D59-492F-8066-E8C517252479 Q26741705-38C99543-772B-4849-A309-013B566803F2 Q26747776-5340228B-42F8-4C82-AB36-338276DCA2B3 Q26748869-89D502DA-B65E-45BD-AF6A-8F50AA77AD67 Q26752919-1C475101-D9E8-4B01-A22F-AF68261F008C Q26771550-0542F0A1-19D7-4EBF-85EA-76054D9A4556 Q26773899-778209FF-0137-4AAC-8DF1-C2A30337AAD1 Q26777184-F2EBBC9A-DA36-46CF-AF1B-C70C90546661 Q26783407-CFB779BF-E64F-4F2F-9ABD-33A0632A97D8 Q26784482-3C9DEC52-1DDC-44D7-9C0C-52C36834F8E0 Q26786549-A482E73F-95FE-4CE1-A52A-F05B63871143 Q26798119-63074863-F028-4D5C-ABAE-73227C9097BD Q26801183-99F823F3-DF4E-4469-A83E-34E680BC62A2 Q26821840-3F0E28CD-2DAB-4E64-BF6F-634289A9F6FB Q26830297-B0FFFC76-1C7A-476C-B951-9BAB0CB47F8F Q28070296-B0CA4CDE-3679-48AC-AEE3-07EAE30EA29B Q28071452-7B2E7D95-7105-43CC-963D-56CFF443D730 Q28072221-E2307C24-D9B0-4FD8-9348-50D2315E2568 Q28072298-B293EAC6-B65B-4031-8FFB-2C44ADE19A4F Q28073656-8CCA458C-1B2F-4916-BBB0-5A50C1DF0B83 Q28073987-6036519B-C440-4596-B348-E7DBB1D540A2 Q28077170-AD0BC0D7-A59C-4227-84F5-8865CBFABAB2 Q28079294-FA962D46-3DE6-4423-A997-8BE09C04C0D0 Q28079757-0CD93EC1-CB80-4A44-A9B6-9D51C38617DA Q28083502-0DE5D801-C271-4C74-BDB1-54F3582998FF Q28083595-B5D9AFC2-DE75-427A-AFCC-C32429A50296 Q28084156-70BF1078-E87F-41CA-989A-4BA96FD207CD Q28275648-56611E51-2C0F-4F87-B0F6-BCDD910DD28F Q28393434-CF03A352-F3D1-426B-AACC-D65A4BA92AE2 Q29994487-A09D688B-B911-4EEC-B618-F4D39F955E05 Q30234612-09B85018-BF24-4D5F-99AC-C0EADF18F937 Q30236043-0F84C5DD-57DF-4CE5-BD09-3FBFB48C1C2F Q30244599-9D983AB1-274A-4C6E-996E-039ED46C6EE4 Q30248925-F2F1F913-BDAB-4C16-B55D-BFDC95E868E8 Q30313892-E5F80D23-94AF-4681-86C3-72B8131F952C Q30713822-B2C8065C-5419-424A-AD9C-94B0ABBE0C7B Q33587438-A22E3D72-BFC2-4F68-87CD-1114F4A872A8 Q33590874-CCD09EC6-996F-48C8-BB1E-1BB99B9582FC

P2860

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

http://www.wikidata.org/entity/Q34467233

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@ast

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@en

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@nl

type

label

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@ast

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@en

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@nl

prefLabel

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@ast

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@en

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@nl

P1433

Q34467233-8D11E61A-2F89-4B14-8283-D92FC7E031AA

P1476

Q34467233-B8E79FD0-77DE-489C-BD86-9C18D0CB7E43

P2093

Q34467233-0256D434-FCA8-4477-8EDA-992996D0BDCC

Q34467233-054A9064-7A14-4DAE-BC31-5C2D162EC570

Q34467233-09D9F820-6049-434B-8AE1-DC13A8048FCB

Q34467233-13402BE6-314B-42AD-A5BF-D12034A16FA9

Q34467233-1B69FD15-4429-4603-B1F8-B9410C07659D

Q34467233-26F91A94-B650-4816-B435-4562671AE75D

Q34467233-5B4977BA-80DE-417F-84AF-C1120C721CAD

Q34467233-78C2DE3A-9D32-4E49-84B0-5A88A0C50755

Q34467233-A5DD3136-6A78-4D82-97E8-EF770194F8B0

Q34467233-AA9229BA-621C-43C6-9D80-444A0503226E

P304

Q34467233-EFCC07C3-A4C2-42D7-A7C6-55D31B64C877

P31

Q34467233-F3888B24-5253-436A-9BBD-E6F94FA782A1

P356

Q34467233-3B61675A-70D2-429A-9D03-DE11F7E75F3D

P407

Q34467233-691797E2-7A27-4524-A986-659D9E0DE9A7

P433

Q34467233-494F359D-A993-49F8-9C9C-0C63DABD9B37

P478

Q34467233-73FA7FB5-1FBE-4A97-AA34-A61D661C19DC

P577

Q34467233-0FEAC781-ADB3-4D4F-90B8-D2C5C313C25D

P698

Q34467233-A5794A9B-5049-46AF-A6E1-22089B48C134

P921

Q34467233-25CD276F-D6E0-4C72-8288-BB3B533F9E09

P356

P1433

The New England Journal of Medicine

P1476

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

@en

P2093

Christelle Lorenzato

http://www.w3.org/2001/XMLSchema#string

Erik S Stroes

http://www.w3.org/2001/XMLSchema#string

Frederick J Raal

http://www.w3.org/2001/XMLSchema#string

Gisle Langslet

http://www.w3.org/2001/XMLSchema#string

Gérald Luc

http://www.w3.org/2001/XMLSchema#string

Jean Bergeron

http://www.w3.org/2001/XMLSchema#string

Jennifer G Robinson

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

Mahfouz El Shahawy

http://www.w3.org/2001/XMLSchema#string

Maurizio Averna

http://www.w3.org/2001/XMLSchema#string

P304

1489-1499

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1501031

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25773378

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio